[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The General Authority for Teaching Hospitals and Institutes\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":155},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,64,90,111,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100615676","micropulse-laser-in-treatment-of-initial-and-refractory-cases-of-center-involved-diabetic-macular-edema-100615676",false,"NCT07295704","Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema","Comparative Evaluation of Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema","Inclusion Criteria:\n\n* Age ≥18 years.\n* Both sexes.\n* Patients with type 1 or 2 diabetes mellitus (DM), best-corrected visual acuity (BCVA) of 20\u002F400 or better, and center-involved DME \\[defined as a central macular thickness (CMT) of \\>250 but \\\u003C700µm measured by spectral-domain optical coherence tomography\\].\n* Patients with any level of non-proliferative diabetic retinopathy or proliferative diabetic retinopathy with adequate panretinal photocoagulation (PRP) and no signs of disease activity determined by fluorescein angiography (FA).\n\nExclusion Criteria:\n\n* Monocular eyes.\n* Chronic renal failure or renal transplant because of diabetic nephropathy.\n* Glycated hemoglobin (HbA1c) of more than 10%.\n* Vitreomacular traction syndrome.\n* Epiretinal membrane.\n* PRP within 4months before the treatment.\n* Intraocular surgery within 6months, including cataract or vitreoretinal operation.\n* Rubeosis iridis.\n* Severe glaucoma.\n* High-risk proliferative diabetic retinopathy.\n* Poor dilation.\n* Increased foveal avascular zone.\n* Any condition that could interfere with optical coherence tomography (OCT) measurement or visual acuity.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the effect of subthreshold 577 nm micropulse laser photocoagulation in the treatment of initial and refractory cases of Center-Involved Diabetic Macular Edema.",[24,25,26,27,28],"Micropulse Laser","Treatment","Initial","Refractory","Center-Involved Diabetic Macular Edema","RECRUITING","2025-12-06",{"date":32,"type":33},"2025-12-22","ACTUAL",{"date":35,"type":33},"2025-10-15",{"date":37,"type":20},"2026-03-30",{"name":39,"class":40},"The General Authority for Teaching Hospitals and Institutes","NETWORK",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100615675","autologous-serum-eye-drops-in-dry-eye-syndrome-100615675","NCT07295691","Autologous Serum Eye Drops in Dry Eye Syndrome","Autologous Serum Eye Drops in Dry Eye Syndrome: Clinical Efficacy and Safety Evaluation","Inclusion Criteria:\n\n* Children aged less than 18 years.\n* Both sexes.\n* Diagnosed with moderate to severe dry eye syndrome (DES) refractory to artificial tears.\n\nExclusion Criteria:\n\n* Active ocular infection.\n* Recent ocular surgery.\n* Systemic immunosuppressive therapy.\n* History of allergy to blood-derived products.",{"count":50,"type":20},70,"INTERVENTIONAL",[53],"NA","This study aims to evaluate the clinical efficacy and safety of autologous serum eye drops (ASEDs) in patients with moderate-to-severe dry eye syndrome who are refractory to conventional artificial tear therapy.",[56,57],"Autologous Serum Eye Drops","Dry Eye Syndrome",{"date":32,"type":33},{"date":60,"type":33},"2025-09-01",{"date":62,"type":20},"2025-12-31",{"name":39,"class":40},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":41},"100602613","original-denis-brawn-brace-versus-its-modification-for-management-of-relapsed-idiopathic-clubfoot-following-ponseti-casting-100602613","NCT07125794","Original Denis Brawn Brace Versus Its Modification for Management of Relapsed Idiopathic Clubfoot Following Ponseti Casting","The Original Denis Brawn Brace Versus Its Modification for Management of Relapsed Idiopathic Clubfoot Following Ponseti Casting: A Retrospective Study.","Inclusion Criteria:\n\n* Age from 2 to 5 years.\n* Both sexes.\n* Relapsed cases.\n* Patients with idiopathic clubfoot.\n\nExclusion Criteria:\n\n* Neurological or syndromic involvement.\n* Presenting with skin or soft-tissue lesions around the foot and ankle.\n* Inadequate documentation.\n* Soft-tissue surgery is needed (except tendo-achilles tenotomy).\n* Irregular plaster casting schedule.","2 Years","5 Years",{"count":74,"type":20},60,"This study aims to compare the effectiveness of the original Denis Brawn brace to its modification in managing relapsed idiopathic clubfoot in patients following Ponseti casting.",[77,78,79,80,81],"Denis Brawn Brace","Modification","Management","Idiopathic Clubfoot","Ponseti Casting","2025-08-10",{"date":84,"type":33},"2025-08-15",{"date":86,"type":33},"2025-05-01",{"date":88,"type":20},"2026-05-01",{"name":39,"class":40},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":108,"leadSponsor":110,"locationsCount":41},"100601301","diffusion-magnetic-resonance-imaging-dmri-in-the-early-evaluation-of-brain-white-matter-diseases-100601301","NCT07108712","Diffusion Magnetic Resonance Imaging (dMRI) in the Early Evaluation of Brain White Matter Diseases","The Role of Diffusion Magnetic Resonance Imaging (dMRI) in the Early Evaluation of Brain White Matter Diseases","Inclusion Criteria:\n\n* Adults aged 18-80 years.\n* Clinical suspicion of early-stage white matter disease.\n* No prior diagnosis of significant neurological disorders (e.g., stroke, brain tumors).\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Contraindications for magnetic resonance imaging (MRI) (e.g., metal implants, pacemakers).\n* Severe psychiatric or cognitive impairment that prevents participation.\n* Control Group: Healthy individuals without any clinical history of neurological diseases, matched by age and sex to the patient cohort.","80 Years",{"count":99,"type":20},150,"To assess the sensitivity and accuracy of diffusion magnetic resonance imaging (MRI), including diffusion-weighted imaging (DWI) metrics, in identifying early-stage changes in brain white matter related to various white matter diseases.",[102,103],"Diffusion Magnetic Resonance Imaging","Brain White Matter Diseases","2025-07-31",{"date":106,"type":33},"2025-08-07",{"date":86,"type":33},{"date":109,"type":20},"2025-12-01",{"name":39,"class":40},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":128,"leadSponsor":129,"locationsCount":41},"100601302","non-invasive-diffusion-weighted-imaging-with-mrcp-in-the-diagnosis-of-neoplastic-biliary-obstruction-100601302","NCT07108725","Non-invasive Diffusion-weighted Imaging With MRCP in the Diagnosis of Neoplastic Biliary Obstruction","The Role of Non-invasive Diffusion-weighted Imaging With MRCP in the Diagnosis of Neoplastic Biliary Obstruction","Inclusion Criteria:\n\n* Adult patients (≥18 years) with clinically suspected biliary obstruction (e.g., jaundice, elevated liver enzymes, cholestasis).\n* Patients who are scheduled for magnetic resonance cholangiopancreatography (MRCP) and have undergone conventional imaging \\[ultrasound or computed tomography (CT)\\].\n* Patients who will undergo further invasive procedures, e.g., endoscopic retrograde cholangiopancreatography (ERCP), biopsy.\n\nExclusion Criteria:\n\n* Patients with contraindications to magnetic resonance imaging (MRI) (e.g., pacemakers, metal implants).\n* Patients who have previously undergone major biliary surgery or stent placement.\n* Pregnant or lactating women.",{"count":119,"type":20},100,"This study aims to evaluate the diagnostic value of non-invasive diffusion-weighted magnetic resonance imaging (DW-MRI) in detecting neoplastic biliary obstruction.",[122,123,124,125],"Non-invasive Diffusion-weighted Imaging","Magnetic Resonance Cholangiopancreatography","Diagnosis","Neoplastic Biliary Obstruction",{"date":106,"type":33},{"date":86,"type":33},{"date":109,"type":20},{"name":39,"class":40},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":137,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":51,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":152,"leadSponsor":154,"locationsCount":41},"100587473","role-of-low-dose-injectable-progesterone-in-triggering-ovulation-100587473","NCT06928844","Role of Low Dose Injectable Progesterone in Triggering Ovulation","Role of Low Dose Injectable Progesterone in Triggering Ovulation: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 20 to 35 years.\n* Infertile women.\n* Basal follicle-stimulating hormone (FSH) level \\\u003C10 mIU\u002Fml.\n\nExclusion Criteria:\n\n* Poor ovarian reserve.\n* Immunological disease.\n* Endometriosis.\n* Uterine abnormality.\n* Body mass index (BMI) \\>30 kg\u002Fm2.\n* Endometrial thickness \\\u003C8 or \\>12 mm on the day of triggering.","FEMALE","20 Years","35 Years",{"count":141,"type":20},120,[53],"The aim of this study is to evaluate the role of low dose injectable progesterone in triggering ovulation.",[145,146,147],"Low Dose","Progesterone","Triggering Ovulation","2025-04-15",{"date":150,"type":33},"2025-04-16",{"date":148,"type":33},{"date":153,"type":20},"2025-08-01",{"name":39,"class":40},""]